In a preclinical setting, AxcessTM delivery technology (Diabetology Ltd., Saint Helier, UK) has incorporated aromatic alcohols into several oral peptides, including CapsulinTM OAD (oral anti-diabetic for T1DM, phase IIb), CapsulinTM IR (insulin replacement for T1DM, phase II), Combulin (for T2DM), oral GLP-1 (for T2DM), and a combination of oral GLP-1 with insulin [107]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.